Current Landscape of Immunotherapy in Breast Cancer
Sylvia Adams(NYU Langone Health), Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), David B. Page(Providence Portland Medical Center), Kevin Kalinsky(Emory University), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Benjamin G. Vincent(University of North Carolina at Chapel Hill), Margaret E. Gatti‐Mays(National Cancer Institute), Elad Sharon(National Cancer Institute), Elizabeth S. Frank(Dana-Farber Cancer Institute), Ian E. Krop(Moffitt Cancer Center), Larissa A. Korde(National Cancer Institute), Mary L. Disis(University of Washington), Julia White(The Ohio State University), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Harry D. Bear(Virginia Commonwealth University), James L. Gulley(National Institutes of Health), Jane Perlmutter(Gemini Computers (United States)), Stephen Chia(BC Cancer Agency), Heather L. McArthur(Cedars-Sinai Medical Center), Joseph A. Sparano(Albert Einstein College of Medicine), Jennifer Fallas Hayes(National Cancer Institute)
Cited by 409
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k